On November 21, Sudeep Pharma’s ₹895-crore initial public offering (IPO) would begin with a price range of ₹563 to ₹593. Before making an investment, be aware of the important dates, financial performance, dangers, and strengths.
The initial public offering (IPO) of Sudeep Pharma is scheduled to begin on Friday, November 21, and end on November 25. The business plans to raise around Rs 895 crore with its book-built IPO. This comprises an offer for sale (OFS) of 1,34,90,726 equity shares with a face value of Rs 1 each and a new issue valued at Rs 95 crore.
The IPO is priced between Rs 563 and Rs 593 per share. Qualified institutional buyers (QIBs) will receive 50% of the overall offering, retail investors will receive 35%, and high-net-worth individuals would receive 15%. The allocation is set for November 26, but Sudeep Pharma’s shares will be listed on the BSE and NSE on November 28.
Sudeep Pharma reported revenue of Rs 511.33 crore for FY25, up from Rs 465.38 crore for FY24. Additionally, net profit increased marginally from Rs 133.15 crore in the previous fiscal year to Rs 138.69 crore in FY25. These financials suggest that the IPO is best suited for long-term investors.
On Friday, November 21, 2025, Sudeep Pharma, a manufacturer of pharmaceutical excipients—products that help the delivery medium but are not the medicine itself, such as coloring additives and preservatives—will have its maiden public offering. A new issuance of 1.6 million shares worth Rs 95 crore and an OFS of up to 13.5 million shares worth Rs 800 crore are included in the offer.
Investors may apply for a minimum of 25 shares per lot, and the IPO price range is still between Rs 563 and Rs 593 per share. The deadline for subscriptions is Tuesday, November 25, 2025. On Friday, November 28, 2025, the company’s stock is anticipated to have its market debut.
MUFG ICICI Securities and IIFL Capital Services are serving as the book-running lead managers, and Intime India has been designated as the issue’s registrar.
Sudeep Pharma intends to use Rs 75.81 crore from the new issuance to purchase equipment for its manufacturing line at the Nandesari plant, according to the Red Herring Prospectus (RHP) submitted to SEBI. The remaining funds will be utilized for standard business operations.
Frequently Asked Questions (FAQ)
1. When does the Sudeep Pharma IPO open and close?
The Sudeep Pharma IPO opens on November 21, 2025, and closes on November 25, 2025.
2. What is the price band for the Sudeep Pharma IPO?
The price band for the IPO is ₹563 to ₹593 per share.
3. What is the total size of the Sudeep Pharma IPO?
The total issue size is approximately ₹895 crore, which includes:
Fresh issue: ₹95 crore
Offer for Sale (OFS): ₹800 crore (1,34,90,726 equity shares)
4. What is the lot size for retail investors?
Investors can apply for a minimum of 25 shares per lot.
5. How are the IPO shares allocated among investor categories?
QIBs (Qualified Institutional Buyers): 50%
Retail Investors: 35%
HNI/NII: 15%
6. When will the IPO allotment results be announced?
The allotment results are expected on November 26, 2025.
7. On which date will Sudeep Pharma be listed on the stock exchanges?
The company’s shares are expected to be listed on November 28, 2025, on both BSE and NSE.
8. What does Sudeep Pharma do?
Sudeep Pharma manufactures pharmaceutical excipients, which are non-active ingredients used in medicines—such as preservatives, binding agents, and coloring additives.
9. How did Sudeep Pharma perform financially in recent years?
Revenue:
FY25: ₹511.33 crore
FY24: ₹465.38 crore
Net Profit:
FY25: ₹138.69 crore
FY24: ₹133.15 crore
The company shows steady revenue growth and consistent profitability.
10. What will the fresh issue proceeds be used for?
As per the RHP filed with SEBI:
₹75.81 crore will be used to purchase equipment for the Nandesari plant.
The remainder will be used for general corporate purposes.
11. Who are the book-running lead managers for this IPO?
MUFG ICICI Securities
IIFL Capital Services
12. Who is the registrar for the Sudeep Pharma IPO?
The registrar for the issue is Intime India.
13. Is Sudeep Pharma IPO good for long-term investment?
The company’s stable financial growth, consistent profits, and expanding manufacturing capabilities suggest that the IPO may be better suited for long-term investors rather than short-term gains. However, investors should evaluate risks and market conditions before investing.
